Patent intelligence · US
US 11253557
Therapeutic bacteriophage compositions
Therapeutic bacteriophage compositions
Patent details — US 11253557
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 22, 2022
- Expiration
- Feb 17, 2042
- Applicant
- Armata Pharmaceuticals, Inc.
- Claims
- 22
- CPC classes
- A61K, A61K35/76
Quick answer
US 11253557 (Therapeutic bacteriophage compositions) is held by Armata Pharmaceuticals, Inc.. Status: granted. Granted Feb 22, 2022. Expires Feb 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Armata Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K35/76
More from Armata Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12268720
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
granted -
US 12239677
Therapeutic bacteriophage compositions for treating Staphylococcus infection
granted -
US 11654166
Therapeutic bacteriophage compositions for treating Staphylococcus infection
granted -
US 10517908
Therapeutic bacteriophage compositions
granted
Frequently asked questions
What is US patent 11253557?
US 11253557 (Therapeutic bacteriophage compositions) is held by Armata Pharmaceuticals, Inc.. Status: granted. Granted Feb 22, 2022. Expires Feb 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11253557?
Armata Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11253557 expire?
Our index shows an expiration date of Feb 17, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.